Salbutamol, a Short Acting Beta-2 Agonist, Reduces Risk and Improves Prognosis of Prostate Cancer. Lehrer S, Rheinstein PH. Am J Clin Oncol 2024 Jul 8. doi: 10.1097/COC.0000000000001134.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lehrer S, Rheinstein PH. Salbutamol, a Short Acting Beta-2 Agonist, Reduces Risk and Improves Prognosis of Prostate Cancer. Am J Clin Oncol 2024 Jul 8. doi: 10.1097/COC.0000000000001134.
PMID: 38973267